4. Discussion
PRIMARY IMMUNE THROMBOCYTOPENIA, DYSFUNCTION, IMMUNE THROMBOCYTOPENIA
Although the first line of treatment (steroid-based) for primary immune thrombocytopenia is effective in most patients [The efficacy of atorvastatin plus N-acetyl cysteine was substantiated because a dysfunction in the endothelial progenitors was demonstrated in patients with immune thrombocytopenia who were resistant to steroids [In a study by Kong and col. [All the patients in the responder group in this study showed significant increases in their platelet counts compared to the counts prior to the study treatment, and even with our limited sample, we can begin to see a tendency for a higher proportion of better responses related to the duration of treatment exposure.It is worth mentioning that the patients who did not continue the study all corresponded to the non-responders group, so the overall response results should be interpreted with caution as well as the differences reported in the mean platelet count after treatment since the non-responder group was not exposed to the study drug for the same proportion of time. The reason for the withdrawal of these patients from this study was due to the withdrawal of consent and patient safety.To our knowledge, this is the first study using this treatment for primary immune thrombocytopenia in our country, and only a few studies have been reported to date in other parts of the world (most of which were performed in China) [Even though second-line treatment options are well established for the treatment of this patient population [